Casdin Capital

Auron Therapeutics, Inc. is a biotechnology company based in Wellesley, Massachusetts, founded in 2018. The company is dedicated to developing innovative therapies for cancer, aiming to shift the traditional focus from merely killing cancer cells to transforming malignant cells into normal, functioning cells through a process known as differentiation therapy. This approach seeks to reactivate the body's innate cellular programs, promoting tumor cell maturation and the restoration of normal tissue. Auron Therapeutics leverages advanced platforms that integrate large genomic datasets and utilize high-throughput flow cytometry to efficiently identify and validate potential drug targets in primary human patient samples. Through its research, the company aims to address significant unmet medical needs in oncology, ultimately striving to deliver life-saving and transformative treatments for cancer patients.

Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Neurogene Inc., established in 2018 and headquartered in New York, specializes in developing genetic medicines for treating neurological disorders. The company focuses on utilizing adeno-associated virus (AAV) vectors to deliver therapeutic genes for conditions such as Charcot-Marie Tooth disease type 4J (CMT4J), Aspartylglucosaminuria (AGU), and an undisclosed Lysosomal Storage Disease (LSD). Neurogene aims to provide effective treatment options where none currently exist, aiming to improve the quality of life for patients and families affected by these rare neurological disorders.

IDRx is a clinical-stage biopharmaceutical company focused on developing precision therapies for oncology, specifically targeting gastrointestinal stromal tumors. The company specializes in designing precision combination therapies that utilize engineered drug combinations to address key tumor escape mechanisms and enhance the duration of therapeutic responses. Through its innovative approach, IDRx aims to transform cancer treatment by enabling healthcare professionals to create targeted cancer medicines tailored to individual patient needs.

BridgeBio Oncology Therapeutics is a biopharmaceutical company specializing in the development of precision oncology therapeutics. It focuses on targeting RAS-dependent cancers, leveraging a profound understanding of RAS signaling biology to create drugs that selectively inhibit RAS-driven PI3K activation and a wide spectrum of KRAS mutants. The company aims to provide patients with tailored treatments that address both active and inactive cancer-driving states.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Avidity Biosciences, Inc. is a biopharmaceutical company based in La Jolla, California, specializing in the development of oligonucleotide-based therapies, particularly through its innovative Antibody Oligonucleotide Conjugates (AOC) platform. This technology aims to address the limitations of traditional oligonucleotide therapies by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide treatments. Avidity's lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic muscle disease. In addition to this, the company is advancing multiple programs focused on muscle-related conditions, including muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Furthermore, Avidity is expanding its research to include immune and other cell types, positioning itself at the forefront of biopharmaceutical innovation for serious diseases.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies aimed at reprogramming ribonucleic acid (RNA) processing to treat various diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary biology platform to discover and develop RNA processing modulators that target previously undruggable disease drivers. Through its REMseq platform, Remix Therapeutics validates therapeutic targets and optimizes chemical compounds, facilitating the identification of patterns in RNA processing. This approach allows for the modulation of gene expression, enabling healthcare practitioners to address the underlying causes of diseases by correcting, enhancing, or eliminating gene messages at their source.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

Orbital Therapeutics is a biotechnology company dedicated to advancing global health through innovative RNA-based medicines. It develops a proprietary platform that combines cutting-edge RNA technology, delivery techniques, data analytics, and automation to create an extensive portfolio of transformative therapies across various disease areas such as vaccines, immunomodulation, protein replacement, and regenerative medicine. The company's mission is to provide patients with novel treatment options for diseases previously considered untreatable or challenging to manage.

Function Oncology is a precision medicine company focused on transforming cancer treatment through its innovative CRISPR-powered personalized functional genomics platform. This platform enables the identification of therapeutic opportunities tailored to individual patients, allowing for a deeper understanding of cancer at a patient-specific level. By leveraging advanced genomic techniques, Function Oncology aims to develop targeted cancer therapies that address the unique characteristics of each patient's disease, ultimately advancing the future of cancer care.

iVexSol Inc. is a biotechnology company based in Worcester, Massachusetts, specializing in the development of lentiviral vector (LVV) manufacturing technology. Established in 2018, the company addresses the critical shortage of LVVs, which serve as essential gene delivery vehicles in the production of cell and gene therapies (CGTs). iVexSol's innovative platform, known as Intelligent Vector Solutions, significantly enhances the scalability and cost-effectiveness of LVV production while reducing the complexity and development time associated with critical reagents. By employing banks of vector-producing cells, the technology allows for the generation of LVVs in higher quantities compared to traditional methods, thereby facilitating quicker scale-up and meeting global demand. This advancement not only shortens clinical development timelines but also aims to improve patient access to life-saving treatments for conditions such as later-stage cancers and various genetic disorders.

Nest Genomics is a lab-agnostic, comprehensive software solution for implementing genomic programs at scale.

Asimov, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on designing and developing genetically engineered therapeutics. Founded in 2017, the company specializes in creating tools for programming living cells, utilizing a multidisciplinary approach that integrates mammalian synthetic biology, computer-aided design, and machine learning. Asimov's platform includes the development of genetic circuits for molecular manufacturing and therapeutic applications, alongside the manufacture of protein biologics, viral vectors, and cell and gene therapies. By combining synthetic biology with biophysical simulations and machine learning algorithms, Asimov aims to optimize the design and production of advanced biologics and gene therapies, thereby contributing to innovations in healthcare.

Vector Biomed is a cutting-edge company specializing in the design and Good Manufacturing Practice (GMP) manufacturing of custom lentiviral vectors. These vectors are essential for the production of gene therapies, including CAR-T cell therapies and stem cell gene therapies. The company provides high-titer, algorithm-optimized lentiviral vectors using a serum-free, chemically-defined process, facilitating a swift transition from therapeutic concept to clinical development. By ensuring the reliability and quality of its vector production, Vector Biomed supports drug developers in efficiently advancing vector-based medicines toward clinical trials and commercialization.

IDRx is a clinical-stage biopharmaceutical company focused on developing precision therapies for oncology, specifically targeting gastrointestinal stromal tumors. The company specializes in designing precision combination therapies that utilize engineered drug combinations to address key tumor escape mechanisms and enhance the duration of therapeutic responses. Through its innovative approach, IDRx aims to transform cancer treatment by enabling healthcare professionals to create targeted cancer medicines tailored to individual patient needs.

Auron Therapeutics, Inc. is a biotechnology company based in Wellesley, Massachusetts, founded in 2018. The company is dedicated to developing innovative therapies for cancer, aiming to shift the traditional focus from merely killing cancer cells to transforming malignant cells into normal, functioning cells through a process known as differentiation therapy. This approach seeks to reactivate the body's innate cellular programs, promoting tumor cell maturation and the restoration of normal tissue. Auron Therapeutics leverages advanced platforms that integrate large genomic datasets and utilize high-throughput flow cytometry to efficiently identify and validate potential drug targets in primary human patient samples. Through its research, the company aims to address significant unmet medical needs in oncology, ultimately striving to deliver life-saving and transformative treatments for cancer patients.

Remix Therapeutics Inc. is a biotechnology company focused on the research and development of innovative small-molecule therapies aimed at reprogramming ribonucleic acid (RNA) processing to treat various diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary biology platform to discover and develop RNA processing modulators that target previously undruggable disease drivers. Through its REMseq platform, Remix Therapeutics validates therapeutic targets and optimizes chemical compounds, facilitating the identification of patterns in RNA processing. This approach allows for the modulation of gene expression, enabling healthcare practitioners to address the underlying causes of diseases by correcting, enhancing, or eliminating gene messages at their source.

Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in the development of protein-based therapeutics for animal health care and veterinary medicine. The company employs a team of veterinary scientists and clinicians dedicated to the discovery and development of biotherapeutics for both pets and farm animals. Invetx aims to transform the animal health industry by leveraging biopharmaceutical technologies to improve health outcomes significantly. By combining deep expertise in veterinary science with innovative therapeutic solutions, Invetx seeks to advance the future of animal care, providing effective treatments that cater to the needs of various animal populations.

Arzeda Corporation is a synthetic biology company based in Seattle, Washington, that focuses on the development and manufacture of enzymes and specialty chemical products. Established in 2008, Arzeda employs intelligent protein design technology, integrating physics-based methodologies with artificial intelligence to create innovative designer proteins and enzymes. Its product portfolio caters to various industries, including polymers, pharmaceuticals, and industrial chemicals, enabling clients to access high-performance solutions that also emphasize cost-effectiveness and sustainability.

Celsius Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for patients suffering from cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a multidisciplinary approach, integrating the expertise of scientists, computational biologists, and clinicians. Celsius Therapeutics utilizes advanced techniques such as single-cell genomic analysis and machine learning to identify and develop innovative therapeutic solutions. By leveraging these cutting-edge technologies, the company aims to create life-changing medicines that address unmet medical needs.

InnoSIGN is a company focused on mRNA-based pathway activity profiling technology that aims to advance precision medicine by enhancing understanding of disease mechanisms. By leveraging a vast library of pathway activity profiles, InnoSIGN seeks to improve diagnostics and drug discovery processes. The company provides researchers with qPCR tests designed for decentralized use, which are available through its service testing facility located in the Netherlands. Through its innovative approach, InnoSIGN aspires to transform the landscape of medical research and treatment by delivering more accurate insights into the causes of diseases.

Deepcell, Inc. is a biotechnology company based in Mountain View, California, that specializes in single-cell analysis technology. Founded in 2015, the company has developed an AI-powered imaging and microfluidics platform that offers a non-invasive method for genetic testing with diagnostic-level accuracy. This platform enables researchers to classify and isolate viable cells based on their morphological characteristics, thus facilitating improved diagnosis and treatment of diseases. By providing detailed genetic health information through ordinary blood samples, Deepcell aims to enhance translational research, diagnostic testing, and therapeutic applications, ultimately reducing the need for invasive procedures in medical diagnostics.

22seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline. It was established in Cambridge, Massachusetts in 2021.

Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, aimed at creating DNA-based products across various industries. Founded in 2013, the company has developed a proprietary method that allows for the reliable, affordable, and sustainable production of long, high-quality, sequence-specific DNA. This innovative technology is designed to support advancements in industrial synthetic biology, personalized therapeutics, precision diagnostics, and has potential applications in information storage and nanotechnology. With a strong executive and scientific team, as well as a robust intellectual property portfolio, Molecular Assemblies is positioned to enhance the capabilities of researchers and contribute to the evolution of DNA-based applications.

Volta Labs, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company specializes in engineering and developing innovative tools for biological automation, focusing on scalable automation solutions for genetic engineering. Its platform is designed to revolutionize genomics research by providing affordable genomic sample preparation and automation for complex biological workflows. By integrating expertise from engineering, surface chemistry, and molecular biology, Volta Labs aims to streamline sample processing and enhance the capabilities of biotech organizations in the next generation of genomic automation.

Creyon Bio is a pre-clinical stage company focused on advancing drug development through a data-driven methodology. It specializes in engineering RNA-based medicines and their components by creating proprietary datasets that inform advanced machine learning models. This innovative approach enables the rapid identification of design rules and engineering principles necessary for the development of safe and effective oligonucleotide-based medicines. By leveraging these insights, Creyon Bio aims to improve the efficiency of the drug development process, ultimately contributing to cost savings in the healthcare sector while catering to diverse patient populations.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines that target the innate immune system. The company employs a structural immunology platform that provides deep insights into molecular structures and mechanisms, enabling precise targeting of the innate immune system. Ventus combines advanced protein engineering capabilities with cutting-edge rational and structure-based drug design tools to create therapeutics aimed at treating autoimmune diseases, inflammatory conditions, and cancer. The company is actively building a diverse pipeline of drug programs that address significant targets within the innate immune system, with the goal of advancing treatments for both acute and chronic inflammatory and immune-related diseases.

Septerna is a biotechnology company focused on the discovery and development of novel small-molecule medicines that target G protein-coupled receptors (GPCRs). The company aims to improve patient outcomes by leveraging advanced drug discovery technologies, including innovative screening methods and structure-based drug design. Septerna utilizes its proprietary Native Complex platform to facilitate industrial-scale drug discovery, enabling researchers to identify effective treatments for a diverse array of diseases. Through its commitment to combining cutting-edge technology with a focus on GPCR targets, Septerna seeks to advance the field of medicine and enhance the quality of life for patients.

Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Fluidigm Corporation develops and markets innovative technologies and tools for life sciences research globally. The company specializes in integrated fluidic circuits that control fluids at the nanoscale, enabling a range of applications in biological research. Its product offerings include analytical systems such as the Helios CyTOF system, the Hyperion imaging system, and the Biomark HD system, along with various assays and reagents designed for immuno-oncology and genetic analysis. Fluidigm also provides preparatory instruments and single-cell microfluidics, such as the C1 and Polaris systems. The company serves a diverse clientele, including academic institutions, clinical research laboratories, biopharmaceutical, biotechnology, and agricultural biotechnology companies, focusing on non-diagnostic and non-clinical applications. Established in 1999 as Mycometrix Corporation, it adopted the name Fluidigm Corporation in 2001 and is headquartered in South San Francisco, California.

Maze Therapeutics, Inc. is a biotechnology company based in South San Francisco, California, established in 2017. The company specializes in developing genetic modifier therapeutics aimed at addressing unmet medical needs. Utilizing its innovative Compass platform, Maze Therapeutics focuses on identifying rare genetic variants that offer protective effects against diseases. By analyzing large-scale human genetic data and employing functional genomics, the company maps these variants to the biological pathways that contribute to specific conditions in patient populations. This approach enables a deeper understanding of target biology and facilitates the development of novel therapies, positioning Maze Therapeutics as a key player in translating genetic insights into effective medicines.

DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life sciences and human health through innovative technology. It has developed the SYNTAX, the world's first benchtop DNA printer, which allows laboratories to produce synthetic oligonucleotides using a novel enzymatic process. This method employs natural enzymes for nucleic acid synthesis, enabling rapid and efficient production of critical genomic experimental precursors. By providing greater control over workflow and accelerating access to results, DNA Script supports researchers in advancing experiments and developing new therapeutics effectively.

ONI is a pioneering company in super-resolution microscopy, dedicated to making advanced imaging technology accessible to researchers. Its flagship product, the Nanoimager, is the first benchtop-sized super-resolution microscope, significantly enhancing usability and precision in biological research. This innovative device allows users to access various super-resolution techniques, including dSTORM, PALM, smFRET, and single-particle tracking, facilitating a deeper understanding of cellular structures and functions. ONI's products are increasingly adopted by leading laboratories worldwide, including institutions such as the Universities of Oxford, Cambridge, and Harvard. The company's mission is to democratize super-resolution fluorescence imaging, thereby accelerating scientific discovery and aiding in disease research by enabling researchers to visualize and comprehend the intricate details of life at the molecular level. Recognized for its contributions to the field, ONI has received accolades for its innovative approach and commitment to enhancing the effectiveness and accessibility of scientific research.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Depixus is a biotechnology company that focuses on advanced genomic analysis through its innovative technology designed for real-time examination of biomolecular interactions. By enabling comprehensive analysis across full genomic regions, the company provides a platform that allows researchers to customize the level of sequencing and epigenetic detail required. This capability facilitates the exploration of new biological pathways, the understanding of disease mechanisms, and the development of precision medicines. Depixus aims to overcome the limitations of current sequencing technologies, which struggle to capture dynamic molecular interactions with single-molecule precision, thus enhancing the ability to unlock valuable insights in genomic research.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at harnessing the untapped genetic diversity of various organisms. By modulating homologous recombination frequencies in eukaryotic cells, Meiogenix enhances natural biodiversity and facilitates the creation of new products. This approach is designed to help businesses tackle pressing global food and industrial challenges, ultimately contributing to sustainable solutions in these sectors.

Exai Bio is a next-generation liquid biopsy company that specializes in the early diagnosis of cancer through its proprietary RNA-based platform. This innovative platform focuses on the analysis of cell-free RNA profiles, particularly orphan non-coding RNA and small RNA sequences that are typically absent in normal tissues but prevalent in tumors. By leveraging advanced artificial intelligence and machine learning algorithms, Exai Bio provides clinical insights into cancer biology, enabling healthcare professionals to identify cancer accurately and at its earliest stages. The company's approach not only enhances diagnostic precision but also informs personalized care treatments for patients.

Nomic is a bioengineering company focused on enhancing access to the human proteome, similar to the accessibility of the human genome. The company is developing the next-generation ELISA platform, known as nELISA, which is designed for high-throughput protein measurement. Nomic's solutions enable scientists to conduct protein profiling efficiently, allowing them to determine the scope and scale of their experiments. The platform features a cost-effective reagent system that integrates seamlessly with existing industry cytometers, facilitating high-throughput analysis and the creation of custom protein panels. By leveraging advanced technology, Nomic aims to empower researchers and nanotechnology developers to utilize DNA as a flexible and programmable linker, effectively addressing challenges such as cross-reactivity in protein measurements.

Stilla Technologies SA is a biotechnology company based in Villejuif, France, with an additional location in Beverly, Massachusetts. Founded in 2013, the company specializes in accelerating the development of next-generation genetic tests through its innovative digital PCR (dPCR) solution known as the Naica System. Utilizing advanced microfluidic technologies, Stilla aims to make dPCR accessible as a standard tool across various life sciences sectors, including research, therapeutics, and genomics. The Naica System offers a flexible platform compatible with multiple chemistries and features multiplex capabilities, providing researchers with high-resolution genetic analysis tools that simplify image processing and data exploration.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Loop Medical, backed by Cerba Healthcare and the Bill & Melinda Gates Foundation, is developing a painless, needleless blood collection device. This modular platform, compatible with standard lab processes, aims to simplify blood sampling for both patients and healthcare professionals, making it more accessible and convenient. The technology, supported by Qloudlab's expertise in connected devices and biosensors, is designed to enhance healthcare outcomes by improving the blood collection process.

Basilard BioTech is a developer of a nanomechanical gene delivery platform aimed at revolutionizing the cell-based therapies market. The company focuses on leveraging the power and diversity of cell functions to address significant unmet clinical needs, particularly in the realm of Cell and Gene Therapies (CGT). By employing a mechanical approach to gene delivery, Basilard BioTech consistently achieves superior transfection rates, enhanced cell viability, and improved yields compared to traditional biological methods. This innovative technology positions the company to significantly advance therapeutic outcomes for diseases that impact millions of individuals globally.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing challenging pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to create a pipeline of drug candidates that target exosites, which are unique and distal binding pockets on enzymes. This innovative approach aims to reprogram enzyme activity, leading to precise and effective therapeutic outcomes, particularly in oncology and inflammation, while also minimizing potential side effects for patients. Exo Therapeutics is committed to unlocking breakthrough therapeutics through its team of experienced researchers and a deep understanding of complex disease mechanisms.

Amplo Biotechnology is a biopharmaceutical company focused on developing innovative Adeno-Associated Viral (AAV) therapies aimed at treating defects related to the neuromuscular junction. These defects can lead to severe health issues, including paralysis and difficulties with breathing and swallowing. The company's lead program, AAV-Dok7, was created by Professor Yuji Yamanashi's research team at the Institute of Medical Science at the University of Tokyo, and it holds promise for addressing various congenital myasthenic syndromes and other rare, severe diseases. Amplo's therapies are administered through intravascular injection, which initiates specific molecular events necessary for effective treatment, thereby enhancing the potential for curative outcomes in affected patients.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Vanqua Bio is a biotechnology company dedicated to discovering and developing innovative medicines for patients with neurodegenerative diseases. The company's proprietary platform employs human genetics and patient-derived neuronal cells to identify and validate novel disease pathways related to lysosomal dysfunction or aberrant immune system activation, aiming to translate these findings into clinically effective treatments.

Xcell Biosciences, Inc. is a San Francisco-based life science company founded in 2012, specializing in innovative technologies for cancer research and immunotherapy. The company has developed proprietary systems that capture, grow, and analyze cancer cells directly from patient blood samples, allowing for precise control over primary cell phenotype and function. This technology enhances the development and production of cell therapies, providing scientists with advanced tools for cell maintenance, expansion, and optimization. By supporting various primary cell types, including immune, stem, and tumor cells, Xcell Biosciences aims to improve predictive therapy development and clinical outcomes for patients undergoing immunotherapy.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

NanoCellect Biomedical, Inc., established in 2009 and headquartered in San Diego, California, specializes in developing innovative flow cytometry and cell sorting solutions for life science researchers. The company's flagship product, the WOLF Cell Sorter, employs a unique closed fluid-path microfluidic cartridge to facilitate efficient cell sorting while mitigating biohazard risks and shear stress issues common in traditional methods. Their portfolio of affordable, compact, and user-friendly instruments and consumables caters to various applications such as drug discovery, single-cell omics, cloning, antibody discovery, and basic research, empowering biomedical scientists with simplified cellular analysis and sorting capabilities.

Zentera Therapeutics is a biopharmaceutical company.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Genomatica, Inc. is a biotechnology company based in San Diego, California, specializing in the development of manufacturing processes for intermediate and basic chemicals derived from renewable feedstocks. Founded in 1998, the company utilizes its proprietary biotechnology platform to create fermentation-based processes and to engineer microorganisms that facilitate the conversion of these feedstocks into essential chemicals. Genomatica has successfully commercialized processes for chemicals such as butanediol, which is used in biodegradable plastics and apparel, and butylene glycol, commonly found in cosmetics and personal care products. The company is also actively working on bio-nylon and has developed a pipeline targeting the production of 20 different chemicals. Recognized for its innovative technologies, Genomatica has received numerous accolades, including the Kirkpatrick Award for outstanding chemical engineering technology and the ICIS Innovation Award for its Brontide butylene glycol.

GeneDx is a company dedicated to providing personalized and actionable health insights that enhance diagnosis and treatment, ultimately improving health outcomes. Positioned at the intersection of diagnostics and data science, GeneDx combines decades of genomic expertise with the capability to interpret clinical data at scale. The company focuses on accelerating the application of genomic information and large-scale clinical data to establish precision medicine as a standard practice in healthcare. GeneDx leads the transformation of healthcare through its comprehensive exome and genome testing services, leveraging one of the largest rare disease data sets in the world. The business operates through two segments: GeneDx, which generates the majority of its revenue, and Legacy Sema4 diagnostics.

Hexagon Bio, Inc. is a biotechnology company that specializes in discovering novel small molecule therapeutics by mining genomic data from fungal genomes. Founded in 2016 and headquartered in Menlo Park, California, Hexagon Bio leverages a proprietary platform that integrates data science, synthetic biology, and automation to identify and engineer drugs. The company's innovative approach focuses on developing targeted therapies for diseases with unmet medical needs by searching for evolutionarily refined molecules and their associated protein targets. Through its unique methodology, Hexagon Bio aims to uncover new medicines encoded within the global metagenome, ultimately striving to improve patient outcomes.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

23andMe, Inc. is a consumer genetics and research company headquartered in Sunnyvale, California, founded in 2006. It specializes in providing direct-to-consumer personal genome services through home-based saliva collection kits. The company offers a range of services, including Health + Ancestry, which provides insights into ancestry, traits, and health, and Ancestry + Traits, which details ancestry breakdown and various trait reports. 23andMe aims to help individuals understand their genetic makeup, enabling users to explore their ancestry, genealogy, and inherited traits. Additionally, the company markets its services to researchers and scientists, offering categorized and searchable genetic data. With a focus on consumer and research services, 23andMe is positioned within the rapidly growing biotech and healthcare sectors, contributing to the understanding of genetics and its implications for health.

Mnemo Therapeutics is a biotechnology company focused on developing immune-based therapies, particularly cell therapies, aimed at providing accessible cures for solid tumors and blood cancers. The company's EnfiniT platform serves as an advanced drug discovery engine that harnesses a specific class of antigens along with various technologies to target tumorous epitopes found across multiple cancer types. By utilizing epigenetic variation and precision genetic engineering technologies, Mnemo Therapeutics creates allogeneic treatments designed to effectively address and overcome these diseases, advancing the field of cancer treatment.

Nautilus Biotechnology Inc. is a development stage life sciences company focused on advancing proteomics to enhance therapeutic development and medical diagnostics. The company aims to create a platform technology that quantifies and unlocks the complexity of the human proteome, ultimately facilitating personalized and predictive medicine. Nautilus has developed a prototype of its innovative single-molecule instrument, the Proteomic Analysis System, which is designed to address challenges in protein analysis that have previously hindered progress in the field. The diverse expertise of its team, which includes professionals from various scientific disciplines such as protein chemistry, molecular biology, and bioinformatics, positions Nautilus to significantly impact drug development and improve human health management.

Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.

Flare Therapeutics is a biotechnology company dedicated to developing small molecule medicines through a novel approach to understanding transcription factors. By identifying 'switch sites,' which are druggable regions crucial for regulating transcription factors, Flare aims to target mutations that lead to various diseases. The company has rapidly advanced its drug discovery efforts, creating an emerging pipeline of programs initially focused on precision oncology. Additionally, Flare's innovative platform holds promise for addressing conditions in neurology, rare genetic disorders, immunology, and inflammation, ultimately enabling medical professionals to transform treatment strategies for patients.

Scribe Biosciences specializes in developing single-cell analysis tools for both clinical and research applications. The company utilizes Printed Droplet Microfluidics (PDM), a technology that allows for precise manipulation of fluids at the picoliter scale. This system employs fluorescence-activated microfluidic droplet sorting and a specialized substrate to handle individual cells and fluid samples with high throughput, enabling detailed studies in areas such as infectious diseases and cancer research.

Dyno Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company specializes in developing adeno-associated virus (AAV) vectors for gene therapy applications. Its innovative platform utilizes artificial intelligence, next-generation DNA synthesis, and high-throughput sequencing to design and optimize AAV capsids, which are crucial for delivering therapeutic genes effectively and safely. By leveraging machine learning and quantitative experimentation, Dyno Therapeutics aims to revolutionize the design of gene vectors, focusing on enhancing cell-targeting capabilities. The company's approach seeks to advance the field of gene therapy, making it possible for researchers to access novel AAV vectors that can facilitate more efficient in vivo delivery of new treatments.

Apton Biosystems, Inc. is a biotechnology company based in Pleasanton, California, founded in 2012. The company specializes in developing advanced optical systems for sequencing and protein detection, utilizing super-resolution technology to analyze molecules that are spaced closer than the wavelength of light. This innovative approach facilitates multi-omic sequencing and single-molecule protein detection, significantly enhancing capabilities in biomarker discovery, early disease detection, and therapeutic monitoring. Apton Biosystems aims to advance preventive health and precision medicine by addressing spatial challenges in high-density sequencing and protein analysis, thus contributing to improved healthcare outcomes.

Treeline Biosciences is a biotechnology company founded in 2021 and based in Stamford, Connecticut. It focuses on developing transformative precision medicines aimed at treating cancer and other serious health conditions. The company employs a comprehensive drug discovery platform that integrates mechanistic biology, medicinal chemistry, computational science, structural biology, and protein science. This multidisciplinary approach is designed to support the development of innovative therapies that can significantly improve patient outcomes in oncology and beyond.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

C2i Genomics, Inc. is a biotechnology company that specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-resection cancer patients. Founded in 2019 and based in New York with a research and development center in Haifa, Israel, the company offers liquid biopsy services that detect subtle changes in tumor DNA to assess cancer recurrence and progression. Its technology supports a bio-platform approach applicable across various cancer types, enhancing the effectiveness of treatments such as surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations, enabling healthcare professionals to monitor treatment responses and detect potential treatment failures or disease recurrence more effectively than traditional methods.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines that target the innate immune system. The company employs a structural immunology platform that provides deep insights into molecular structures and mechanisms, enabling precise targeting of the innate immune system. Ventus combines advanced protein engineering capabilities with cutting-edge rational and structure-based drug design tools to create therapeutics aimed at treating autoimmune diseases, inflammatory conditions, and cancer. The company is actively building a diverse pipeline of drug programs that address significant targets within the innate immune system, with the goal of advancing treatments for both acute and chronic inflammatory and immune-related diseases.

SeQure DX is a biotechnology company specializing in genomics diagnostics for CRISPR-based gene editing therapies. It develops technologies that identify potential off-target sites prior to therapy initiation, ensuring comprehensive confirmation of actual edits. This enables safer and more effective gene editing therapeutics development, benefiting both researchers and patients.

Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

Insitro, Inc. is a data-driven company focused on drug discovery and development, particularly targeting nonalcoholic steatohepatitis (NASH). Founded in 2018 by Daphne Koller and based in South San Francisco, California, Insitro harnesses machine learning and high-throughput biology to revolutionize the process of drug discovery. The company creates extensive functional genomic data sets and integrates them with patient data through innovative machine learning techniques. This approach allows Insitro to build predictive models that enhance target selection, streamline the design of therapeutics, and optimize drug development strategies. By addressing critical challenges in pharmaceutical research and development, Insitro aims to accelerate the delivery of new and effective treatments to patients.

Monte Rosa Therapeutics is a biotechnology company dedicated to developing innovative cancer therapeutics through the modulation of protein degradation pathways. Specializing in molecular glue degraders (MGDs), the company utilizes the body's natural mechanisms for protein destruction to selectively degrade proteins that are relevant to therapeutic outcomes. Employing its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, Monte Rosa identifies target proteins for degradation by MGDs from its extensive library of over 50,000 molecules. The company's most advanced product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for the treatment of MYC-driven tumors. Monte Rosa Therapeutics aims to deliver pioneering therapies for cancer and potentially other diseases through its innovative approaches.

Palamedrix is a biotechnology company founded in 2017 by Shane Bowen and based in San Diego, California. It specializes in developing a multi-omic platform that aims to advance life sciences and medicine. By leveraging DNA nanotechnology, Palamedrix creates solutions for biomedical applications that provide comprehensive data. This innovative platform enables healthcare professionals and patients to obtain a detailed and accurate understanding of an individual's biochemistry through a single test, thereby enhancing diagnostic capabilities and treatment options.

Tenaya Therapeutics is a preclinical stage biotechnology company based in South San Francisco, California, specializing in the development of innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs a multipronged approach to address the fundamental cellular pathologies associated with cardiac muscle disease. Tenaya Therapeutics advances its product candidates through three primary platforms: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads to cardiac fibroblasts, and a precision medicine platform that offers personalized treatment strategies. Through its research, the company aims to enable physicians to regenerate heart tissue and tackle various forms of cardiomyopathies effectively.

Pipeline Therapeutics Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of small molecules aimed at neuroregeneration. Founded in 2017, the company focuses on promoting functional recovery for various neurological disorders. Its lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics has a portfolio of earlier-stage programs, including PIPE-307, which targets remyelination and axonal repair to address conditions like multiple sclerosis. By harnessing the natural repair processes of different nervous system cell types, the company seeks to provide innovative treatments that repair damage within the nervous system.

Notch Therapeutics Inc. is an immune cell therapy company focused on developing gene-edited allogenic T cell therapies for cancer treatment. Founded in 2018 and headquartered in Toronto, Canada, the company specializes in induced pluripotent stem cell (iPSC) AlloCAR therapy products targeting non-Hodgkin lymphoma, leukemia, and multiple myeloma. Notch Therapeutics has created a proprietary T-cell production platform that allows for precise control of Notch signaling, a critical factor in T-cell development. This innovative approach addresses key limitations in cell therapy development, enabling the design and manufacture of a consistent and limitless supply of therapeutic T cells. The technology empowers healthcare professionals to engineer stem cells tailored to the complex biology of various diseases, thereby enhancing the efficacy of cell therapies.

Orchard Therapeutics is a biopharmaceutical company based in London, focused on developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which aims to modify a patient's hematopoietic stem cells to create a personalized treatment through a single administration. Orchard's product portfolio includes Strimvelis, the first gene therapy approved by the European Medicines Agency for adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company is advancing several clinical programs, including OTL-101 for ADA-SCID, OTL-200 for metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Additionally, Orchard has a robust preclinical pipeline targeting various mucopolysaccharidosis types. Founded in 2015, Orchard Therapeutics collaborates with leading institutions in the field to enhance its research and development efforts.

Auron Therapeutics, Inc. is a biotechnology company based in Wellesley, Massachusetts, founded in 2018. The company is dedicated to developing innovative therapies for cancer, aiming to shift the traditional focus from merely killing cancer cells to transforming malignant cells into normal, functioning cells through a process known as differentiation therapy. This approach seeks to reactivate the body's innate cellular programs, promoting tumor cell maturation and the restoration of normal tissue. Auron Therapeutics leverages advanced platforms that integrate large genomic datasets and utilize high-throughput flow cytometry to efficiently identify and validate potential drug targets in primary human patient samples. Through its research, the company aims to address significant unmet medical needs in oncology, ultimately striving to deliver life-saving and transformative treatments for cancer patients.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

FogPharma is a biotechnology company focused on developing innovative therapies for cancer treatment through its proprietary cell-penetrating mini proteins (CPMPs). Founded by Greg Verdine, a leader in drug discovery, the company aims to target cancer-causing proteins within cells that are typically inaccessible to traditional drugs. This novel approach allows for the neutralization of these proteins, potentially transforming the treatment landscape for cancer-related diseases. FogPharma collaborates with leading experts in cancer biology and therapy, fostering a network of researchers, investors, and cancer patients dedicated to advancing its mission. The company is committed to delivering this new class of medicines to improve patient outcomes and enhance quality of life for individuals affected by cancer.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

Neurogene Inc., established in 2018 and headquartered in New York, specializes in developing genetic medicines for treating neurological disorders. The company focuses on utilizing adeno-associated virus (AAV) vectors to deliver therapeutic genes for conditions such as Charcot-Marie Tooth disease type 4J (CMT4J), Aspartylglucosaminuria (AGU), and an undisclosed Lysosomal Storage Disease (LSD). Neurogene aims to provide effective treatment options where none currently exist, aiming to improve the quality of life for patients and families affected by these rare neurological disorders.

Faze Medicines is a biotechnology company based in Cambridge, Massachusetts, founded in 2020. It focuses on developing small molecule drugs targeting key drivers of disease pathology, with initial therapeutic areas including amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). The company employs advanced screening and proteomics techniques to define condensate interaction networks, aiming to pioneer innovative therapeutics based on biomolecular condensates. Through its research, Faze Medicines seeks to provide effective treatments for complex diseases such as ALS and frontotemporal dementia (FTD).

PanTHERA CryoSolutions specializes in designing and manufacturing advanced cryopreservation solutions aimed at preserving cells, tissues, and small molecules used in clinical research. The company focuses on developing patented ice recrystallization inhibitors that minimize ice crystal formation during the freezing process, thereby protecting cellular integrity and enhancing post-thaw performance. By allowing for the use of less expensive storage and transportation methods, PanTHERA CryoSolutions reduces reliance on liquid nitrogen in cell treatment applications. Their scientific expertise drives the creation of evidence-based products that not only lower toxicity but also improve the stability of biological materials during extended frozen storage, ultimately benefiting the field of cell therapeutics.

iVexSol Inc. is a biotechnology company based in Worcester, Massachusetts, specializing in the development of lentiviral vector (LVV) manufacturing technology. Established in 2018, the company addresses the critical shortage of LVVs, which serve as essential gene delivery vehicles in the production of cell and gene therapies (CGTs). iVexSol's innovative platform, known as Intelligent Vector Solutions, significantly enhances the scalability and cost-effectiveness of LVV production while reducing the complexity and development time associated with critical reagents. By employing banks of vector-producing cells, the technology allows for the generation of LVVs in higher quantities compared to traditional methods, thereby facilitating quicker scale-up and meeting global demand. This advancement not only shortens clinical development timelines but also aims to improve patient access to life-saving treatments for conditions such as later-stage cancers and various genetic disorders.

Mnemo Therapeutics is a biotechnology company focused on developing immune-based therapies, particularly cell therapies, aimed at providing accessible cures for solid tumors and blood cancers. The company's EnfiniT platform serves as an advanced drug discovery engine that harnesses a specific class of antigens along with various technologies to target tumorous epitopes found across multiple cancer types. By utilizing epigenetic variation and precision genetic engineering technologies, Mnemo Therapeutics creates allogeneic treatments designed to effectively address and overcome these diseases, advancing the field of cancer treatment.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

SomaLogic, Inc. is a commercial-stage company based in Boulder, Colorado, specializing in protein biomarker discovery and clinical diagnostics. Founded in 1999, the company has developed advanced technologies such as SOMAmers, slow off-rate modified aptamers that specifically bind to target proteins, and the SOMAscan platform, which facilitates comprehensive protein measurement. This innovative approach allows for the analysis of protein biomarker signatures, significantly enhancing the understanding of health and disease beyond traditional genomic methods. SomaLogic's products are utilized in a variety of applications, including diagnostics for conditions in oncology, neurology, and cardiovascular and metabolic diseases, as well as in drug discovery and development. The company also offers diagnostic tests and protein measurement solutions for life science and biopharma researchers, contributing to advancements in medical science.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

Oxford Nanopore Technologies Limited is a biotechnology company specializing in the development and commercialization of nanopore-based sequencing technology for the analysis of DNA, RNA, proteins, and small molecules. Its innovative product lineup includes the portable MinION device, the benchtop PromethION, and the GridION system, all of which enable real-time data streaming and scalable sequencing for a variety of applications in scientific research, personalized medicine, environmental monitoring, and agriculture. The Flongle offers smaller, on-demand sequencing solutions, catering to users requiring rapid insights. Operating in over 80 countries, Oxford Nanopore's technology is designed for accessibility and ease of use, featuring straightforward library preparation and automated solutions. The company maintains a robust patent portfolio, supporting its ongoing research and development in both biological and solid-state nanopore technologies. Founded in 2005 and based in Oxford, United Kingdom, Oxford Nanopore Technologies also has offices in multiple countries, including the United States, China, and Germany.

Cedilla Therapeutics, Inc. is a biotechnology company focused on developing targeted small-molecule therapeutics for cancer and diseases linked to protein dysregulation. The company employs innovative strategies to destabilize oncoprotein targets, utilizing methods such as direct ligand-induced degradation, disruption of stabilizing protein-protein interactions, and the identification of upstream regulators that affect protein stability. Cedilla's comprehensive approach also includes large-scale proteomic analyses to map protein susceptibility, enhancing the potential for effective therapies. By concentrating on the transitions between stable and susceptible protein states, Cedilla aims to create novel treatments that broaden the applicability of small molecule therapeutics beyond oncology. Founded in 2017 and headquartered in Cambridge, Massachusetts, the company was formerly known as Protein Stability Newco, Inc. before rebranding in 2018.

Vineti, Inc. is a technology company focused on advancing the development and delivery of personalized therapies, particularly in the realm of cell and gene treatments for serious conditions like cancer. Founded in 2016 and headquartered in San Francisco, California, Vineti offers a cloud-based platform known as the Personalized Therapy Management (PTM) platform. This platform integrates various aspects of the therapeutic supply chain, including operations, manufacturing, quality assurance, and regulatory compliance, to streamline and automate processes. It addresses critical challenges faced by patients, healthcare providers, pharmaceutical companies, and regulatory bodies in the commercialization of personalized medicine. By enhancing supply chain orchestration and ensuring compliance with regulatory standards, Vineti aims to expand patient access to innovative therapies. The company also maintains regional offices in Bethesda, Maryland, and Yerevan, Armenia.

A2 Biotherapeutics, Inc. is a biotechnology company dedicated to developing innovative cell therapies for tumor cancer treatment. Based in Agoura Hills, California, the company utilizes its proprietary Tmod™ platform to create T cell therapies that accurately differentiate between solid tumors and normal cells. This platform allows for the identification and engineering of binders derived from antibodies or T cell receptors, optimizing precision in targeting cancer cells. A2 Biotherapeutics specifically addresses various cancer types, including head, neck, pancreatic, colorectal, and lung cancers, as well as cancer testis antigens. By engineering T cells to recognize genetic material loss in tumors, the company aims to selectively kill tumor cells while sparing healthy tissue. Founded in 2017, A2 Biotherapeutics continues to advance the field of cancer therapy through its innovative approaches.

Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, specializing in the development of protein-based therapeutics for animal health care and veterinary medicine. The company employs a team of veterinary scientists and clinicians dedicated to the discovery and development of biotherapeutics for both pets and farm animals. Invetx aims to transform the animal health industry by leveraging biopharmaceutical technologies to improve health outcomes significantly. By combining deep expertise in veterinary science with innovative therapeutic solutions, Invetx seeks to advance the future of animal care, providing effective treatments that cater to the needs of various animal populations.

Monte Rosa Therapeutics is a biotechnology company dedicated to developing innovative cancer therapeutics through the modulation of protein degradation pathways. Specializing in molecular glue degraders (MGDs), the company utilizes the body's natural mechanisms for protein destruction to selectively degrade proteins that are relevant to therapeutic outcomes. Employing its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, Monte Rosa identifies target proteins for degradation by MGDs from its extensive library of over 50,000 molecules. The company's most advanced product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for the treatment of MYC-driven tumors. Monte Rosa Therapeutics aims to deliver pioneering therapies for cancer and potentially other diseases through its innovative approaches.